skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 60,376  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Material Type:
Article
Add to My Research

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of clinical oncology, 2022-01, Vol.40 (2), p.127-137 [Peer Reviewed Journal]

2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.21.02229 ;PMID: 34818112

Full text available

2
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Material Type:
Article
Add to My Research

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2780-2788 [Peer Reviewed Journal]

2015 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.58.3377 ;PMID: 26014293

Full text available

3
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Material Type:
Article
Add to My Research

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

Journal of clinical oncology, 2013-12, Vol.31 (34), p.4311-4318 [Peer Reviewed Journal]

2015 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2013.51.4802 ;PMID: 24145345

Full text available

4
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
Material Type:
Article
Add to My Research

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

Journal of clinical oncology, 2020-09, Vol.38 (26), p.3051-3061 [Peer Reviewed Journal]

Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.19.03357 ;PMID: 32730186

Full text available

5
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Material Type:
Article
Add to My Research

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

The lancet oncology, 2021-05, Vol.22 (5), p.643-654 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;2021. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00065-6 ;PMID: 33857412

Full text available

6
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma
Material Type:
Article
Add to My Research

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma

JNCI : Journal of the National Cancer Institute, 2014-09, Vol.106 (9), p.1 [Peer Reviewed Journal]

The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;Copyright Oxford Publishing Limited(England) Sep 2014 ;The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. 2014 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/dju246 ;PMID: 25217772 ;CODEN: JNCIEQ

Full text available

7
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Material Type:
Article
Add to My Research

A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients

Cancer immunology research, 2019-07, Vol.7 (7), p.1162-1174 [Peer Reviewed Journal]

2019 American Association for Cancer Research. ;ISSN: 2326-6066 ;EISSN: 2326-6074 ;DOI: 10.1158/2326-6066.cir-18-0500 ;PMID: 31088844

Full text available

8
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis
Material Type:
Article
Add to My Research

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis

Journal of clinical oncology, 2015-03, Vol.33 (7), p.773-781 [Peer Reviewed Journal]

2015 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.57.4756 ;PMID: 25605840

Full text available

9
Melanoma
Material Type:
Article
Add to My Research

Melanoma

The Lancet (British edition), 2018-09, Vol.392 (10151), p.971-984 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 15, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)31559-9 ;PMID: 30238891

Full text available

10
The Rapid Rise in Cutaneous Melanoma Diagnoses
Material Type:
Article
Add to My Research

The Rapid Rise in Cutaneous Melanoma Diagnoses

The New England journal of medicine, 2021-01, Vol.384 (1), p.72-79 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsb2019760 ;PMID: 33406334

Full text available

11
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Material Type:
Article
Add to My Research

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1708539 ;PMID: 28891408

Full text available

12
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Material Type:
Article
Add to My Research

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Cancer cell, 2019-02, Vol.35 (2), p.238-255.e6 [Peer Reviewed Journal]

2019 Elsevier Inc. ;Copyright © 2019 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2019.01.003 ;PMID: 30753825

Full text available

13
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Material Type:
Article
Add to My Research

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Journal of clinical oncology, 2015-10, Vol.33 (28), p.3193-3198 [Peer Reviewed Journal]

2015 by American Society of Clinical Oncology. ;2015 by American Society of Clinical Oncology 2015 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.60.8448 ;PMID: 26282644

Full text available

14
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Material Type:
Article
Add to My Research

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1239-1246 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.32.4327 ;PMID: 21343559

Full text available

15
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Material Type:
Article
Add to My Research

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

Cancer cell, 2017-05, Vol.31 (5), p.711-723.e4 [Peer Reviewed Journal]

2017 Elsevier Inc. ;Copyright © 2017 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2017.04.003 ;PMID: 28486109

Full text available

16
Targeting Oncogenic Drivers and the Immune System in Melanoma
Material Type:
Article
Add to My Research

Targeting Oncogenic Drivers and the Immune System in Melanoma

Journal of clinical oncology, 2013-02, Vol.31 (4), p.499-506 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.5568 ;PMID: 23248252

Full text available

17
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Material Type:
Article
Add to My Research

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

The lancet oncology, 2012-08, Vol.13 (8), p.782-789 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 2012 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(12)70269-3 ;PMID: 22805292 ;CODEN: LANCAO

Full text available

18
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Material Type:
Article
Add to My Research

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Nature medicine, 2021-02, Vol.27 (2), p.301-309 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2021. ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-020-01188-3 ;PMID: 33558722

Full text available

19
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Material Type:
Article
Add to My Research

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2904-2909 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.33.9275 ;PMID: 21690468

Full text available

20
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Material Type:
Article
Add to My Research

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

The lancet oncology, 2018-03, Vol.19 (3), p.310-322 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30078-0 ;PMID: 29449192

Full text available

Results 1 - 20 of 60,376  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (55,178)

Refine My Results

Creation Date 

From To
  1. Before 1963  (832)
  2. 1963 To 1977  (2,841)
  3. 1978 To 1992  (8,403)
  4. 1993 To 2008  (20,988)
  5. After 2008  (27,383)
  6. More options open sub menu

Language 

  1. English  (57,346)
  2. Japanese  (5,940)
  3. German  (1,430)
  4. Spanish  (1,043)
  5. Portuguese  (777)
  6. French  (560)
  7. Norwegian  (53)
  8. Swedish  (53)
  9. Chinese  (35)
  10. Italian  (29)
  11. Korean  (24)
  12. Turkish  (24)
  13. Hungarian  (22)
  14. Czech  (22)
  15. Russian  (18)
  16. Polish  (18)
  17. Serbian  (16)
  18. Croatian  (15)
  19. Romanian  (4)
  20. Persian  (4)
  21. More options open sub menu

Searching Remote Databases, Please Wait